3 month supply tirzepatide Compounded (GLP-1/GIP) 1 and GIP therapy takes appetite regulation and metabolism support to the next level Zepbound Vials Online | Zepbound
Description
Clinical trials have shown improvements in metabolic parameters as well as sustained long-term weight loss
In STEP 1, the largest clinical trial, semaglutide takers lost, on average, 15 percent of their initial weight, or about 35 pounds, after 68 weeks
PlexusDx Precision Peptide Genetic Test ($99 add-on) analyzes 14 peptide-pathway genes and 150+ genetic insights, including GLP1R rs6923761 and GIPR rs1800437variants that predict your appetite-suppression response and metabolic resilience
Care decisions center on symptom severity, persistence, and impact on daily activities
